Treatment strategies in advanced stage follicular lymphoma

Marinus H. J. van Oers; Marie José Kersten

doi:10.1016/j.beha.2011.03.003

Treatment strategies in advanced stage follicular lymphoma

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Although the introduction of anti-CD20 monoclonal antibodies has improved the outcome of patients with follicular lymphoma, a curative treatment is still not available. Many questions still remain to be answered: when should treatment be initiated? Is there an optimal first line treatment and can this treatment be individualized on the basis of prognostic markers? What is the best treatment strategy for relapsed follicular lymphoma and what is the place of the many novel agents? Should maintenance treatment be given to all patients and how? In the present review we will address these questions

Original language	English
Pages (from-to)	187-201
Journal	Best practice & research. Clinical haematology
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/j.beha.2011.03.003
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.beha.2011.03.003

Cite this

@article{baa8043d6b054f6292b40b469c554fc5,

title = "Treatment strategies in advanced stage follicular lymphoma",

abstract = "Although the introduction of anti-CD20 monoclonal antibodies has improved the outcome of patients with follicular lymphoma, a curative treatment is still not available. Many questions still remain to be answered: when should treatment be initiated? Is there an optimal first line treatment and can this treatment be individualized on the basis of prognostic markers? What is the best treatment strategy for relapsed follicular lymphoma and what is the place of the many novel agents? Should maintenance treatment be given to all patients and how? In the present review we will address these questions",

author = "\{van Oers\}, \{Marinus H. J.\} and Kersten, \{Marie Jos{\'e}\}",

year = "2011",

doi = "10.1016/j.beha.2011.03.003",

language = "English",

volume = "24",

pages = "187--201",

journal = "Best practice \& research. Clinical haematology",

issn = "1521-6926",

publisher = "Bailliere Tindall Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment strategies in advanced stage follicular lymphoma

AU - van Oers, Marinus H. J.

AU - Kersten, Marie José

PY - 2011

Y1 - 2011

N2 - Although the introduction of anti-CD20 monoclonal antibodies has improved the outcome of patients with follicular lymphoma, a curative treatment is still not available. Many questions still remain to be answered: when should treatment be initiated? Is there an optimal first line treatment and can this treatment be individualized on the basis of prognostic markers? What is the best treatment strategy for relapsed follicular lymphoma and what is the place of the many novel agents? Should maintenance treatment be given to all patients and how? In the present review we will address these questions

AB - Although the introduction of anti-CD20 monoclonal antibodies has improved the outcome of patients with follicular lymphoma, a curative treatment is still not available. Many questions still remain to be answered: when should treatment be initiated? Is there an optimal first line treatment and can this treatment be individualized on the basis of prognostic markers? What is the best treatment strategy for relapsed follicular lymphoma and what is the place of the many novel agents? Should maintenance treatment be given to all patients and how? In the present review we will address these questions

U2 - 10.1016/j.beha.2011.03.003

DO - 10.1016/j.beha.2011.03.003

M3 - Article

C2 - 21658618

SN - 1521-6926

VL - 24

SP - 187

EP - 201

JO - Best practice & research. Clinical haematology

JF - Best practice & research. Clinical haematology

IS - 2

ER -

Treatment strategies in advanced stage follicular lymphoma

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this